Navigation Links
Array BioPharma to Present at the Bank of America Merrill Lynch Healthcare Conference and the UBS Global Healthcare Conference
Date:5/8/2013

BOULDER, Colo., May 8, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas and the UBS Global Healthcare conference in New York City.  The public is welcome to participate in the conferences through webcasts on the Array BioPharma website:  www.arraybiopharma.com.(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)Event:Bank of America Merrill Lynch Healthcare ConferenceDate:Thursday, May 16, 2013Time:11:20 a.m. PDT Location:Encore at the Wynn, Las Vegas, NVEvent:UBS Global Healthcare ConferenceDate:Tuesday, May 21, 2013Time:8:30 a.m. EDT Location:Sheraton New York Hotel, NYC, NYAbout Array BioPharma Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions. Novartis expects to begin Phase 3 trials evaluating Array-invented MEK162 in NRAS-mutant melanoma and in BRAF-mutant melanoma in 2013.  In addition, Array will begin a Phase 3 trial evaluating MEK162 in low-grade serous ovarian cancer under the license agreement with Novartis in 2013.  AstraZeneca expects to begin Phase 3 or pivotal registration trials with selumetinib (an Array-invented drug) in non-small cell lung cancer and thyroid cancer during the second half of 2013.  Three other Array-invented drugs are also approaching Phase 3 or pivota
'/>"/>

SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
2. Maine Manufacturing, LLC Announces Global Distribution of FAST® Protein Array Products
3. Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks
4. Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
5. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
6. Solar nanowire array may increase percentage of suns frequencies available for energy conversion
7. Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
8. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
9. John A. Orwin Joins Array BioPharma Board Of Directors
10. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
11. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... July 6, 2015  Approximately 1% of the population ... their chromosomes. These individuals are three times more likely ... in one of the nation,s leading medical journals by ... Canada.  Photo - http://photos.prnewswire.com/prnh/20150706/230685 ... (HHV-6) causes roseola (also known as "sixth disease") and ...
(Date:7/6/2015)... ... July 06, 2015 , ... Discovery of new biomarkers ... key drivers of the global molecular diagnostics market. BCC Research reveals in its ... new companion diagnostic tests will increase demand for inexpensive and accurate tests for ...
(Date:7/6/2015)... , July 6, 2015  Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), ... Patricia Scheller , Viveve,s Chief Executive Officer, and Scott ... VirtualInvestorConferences.com on July 9, 2015. , , , ... , , , TIME:     , , , ... , , , http://tinyurl.com/viveve   , ...
(Date:7/6/2015)... July 6, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") ... agreement with Novella Clinical (Novella), to conduct ... with newly diagnosed glioblastoma. Novella is a full-service, global ... small to mid-sized oncology companies. The ICT-107 phase 3 ... US, Europe and ...
Breaking Biology Technology:Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 2Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 3Viveve to Webcast Live at VirtualInvestorConferences.com 2Viveve to Webcast Live at VirtualInvestorConferences.com 3ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2
... Nokia,s new website, which provides innovative ways to interact with thought ... , ... San Francisco, CA (PRWEB) February 12, 2009 -- ... genetic testing service 23andme, says that as we further our understanding ...
... OriGene Technologies, Inc. ("OriGene") today announced it ... private equity financing. With this financing, OriGene completed ... Shenzhen P&A Biotech, a manufacturer and provider of ... this acquisition OriGene completes the establishment of its ...
... for the control of parasites in agriculture and medicine, today announced that ... will further its efforts to create solutions for one of the major ... ... (PREWB) February 11, 2009 -- Biotechnology firm Divergence, Inc., a world leader ...
Cached Biology Technology:Famed IT Investor and Director of 23andme Esther Dyson Identifies on IdeasProject.com Genetic Information as an Extremely Disruptive Force 2Famed IT Investor and Director of 23andme Esther Dyson Identifies on IdeasProject.com Genetic Information as an Extremely Disruptive Force 3OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China 2Divergence Raises $11.8 Million in Series C Financing 2Divergence Raises $11.8 Million in Series C Financing 3
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
(Date:6/23/2015)... Fla. , June 23, 2015 /PRNewswire/ ... management and authentication solutions, today announced enhanced functionality ... multi-factor authentication solution.  The enhancements build on ... of the DigitalPersona Altus platform and provide ... compatibility. In today,s environment of ...
(Date:6/17/2015)... and HILDEN, Germany , June 17, 2015 ... Frankfurt Prime Standard: QIA) today launched new Investigator ® ... laboratories in the United States . The ... analyze multiple key genomic markers (short tandem repeats or STRs) ... Sensor to evaluate the quality of DNA in each sample, ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... at Memorial Sloan-Kettering Cancer Center (MSKCC) have shown for ... blood disorders may be inherited. Their research, published online ... genetic sequence abnormality that enhances the likelihood of acquiring ... diseases. The investigators carried out a genome-wide study ...
... (NIEHS), part of the National Institutes of Health (NIH), ... of Toxicology (SOT) meeting in Baltimore, Md. Scientists from ... NIEHS administers, as well as their grantees and collaborators, ... the field of toxicology. Why: The SOT Annual Meeting ...
... researchers at Kansas State,University, with collaboration from Epitopix ... against E. coli O157 in beef ... focus on the post-harvest food safety,aspect, whether it,s ... Thomson of,K-State,s College of Veterinary Medicine. Thomson is ...
Cached Biology News:Hear about emerging trends in toxicology research 2K-State researchers help Epitopix license the United States' first E. coli O157 vaccine for cattle 2